<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01930006</url>
  </required_header>
  <id_info>
    <org_study_id>265-106</org_study_id>
    <nct_id>NCT01930006</nct_id>
  </id_info>
  <brief_title>Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State</brief_title>
  <official_title>Phase 1 Single Dose 2-Way Crossover Comparative Bioavailability Study Of Two Oral Formulations Of MGCD265 In Healthy Male And Female Subjects - Fasting State</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mirati Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mirati Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study two MGCD265 oral formulations at dose level of 100 mg are administered to&#xD;
      healthy male and female subjects under fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to compare the rate and extent of absorption of two MGCD265&#xD;
      oral formulations at a dose level of 100 mg administered to healthy male and female subjects&#xD;
      under fasting conditions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the bioavailability of two MGCD265 formulations.</measure>
    <time_frame>Two months</time_frame>
    <description>To compare the rate and extent of absorption of two MGCD265 oral formulations at dose level of 100 mg administered as 1 x 100 mg oral dose (Formulation A) and 2 x 50 mg oral dose (Formulation B) under fasting conditions.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Advanced Malignancies</condition>
  <arm_group>
    <arm_group_label>MGCD265</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MGCD265</intervention_name>
    <arm_group_label>MGCD265</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male or female subjects ≥18 to ≤55 years of age who are willing and able to&#xD;
             provide informed consent prior to performing any study related procedures&#xD;
&#xD;
          2. Females of childbearing potential who are using a stable contraceptive method at least&#xD;
             30 days prior to screening and who are willing to use one of the following acceptable&#xD;
             birth control methods until 30 days after the last dose of study drug:&#xD;
&#xD;
               1. Abstinence&#xD;
&#xD;
               2. Hormonal contraceptives (birth control pills, injectable/ implantable/ insertable&#xD;
                  hormonal birth control products, transdermal patch) for at least 3 months prior&#xD;
                  to the first dose of the study drug and male condom and intravaginal spermicide&#xD;
&#xD;
               3. Intra-uterine contraceptive device (IUD) in place for at least 3 months prior to&#xD;
                  the first dose of study drug plus spermicide and male condom&#xD;
&#xD;
               4. Male condom and diaphragm plus spermicide;&#xD;
&#xD;
               5. Male condom and cervical cap plus spermicide;&#xD;
&#xD;
               6. Surgical sterilization of the partner(s) (vasectomy for 6 months minimum prior to&#xD;
                  the first dose of study drug)&#xD;
&#xD;
          3. Female subjects will be considered of non childbearing potential and eligible if one&#xD;
             of the following condition is met:&#xD;
&#xD;
               1. Amenorrhea for at least 1 year, with confirmation by a follicle-stimulating&#xD;
                  hormone (FSH ≥ 40 mIU/mL)&#xD;
&#xD;
               2. Hysterectomy&#xD;
&#xD;
               3. Bilateral oophorectomy&#xD;
&#xD;
               4. Bilateral tubal ligation&#xD;
&#xD;
          4. Male subjects must agree to be abstinent or use the following acceptable contraception&#xD;
             methods in collaboration with their female partner from the time of taking the first&#xD;
             dose until 3 months after the last dose of study drug:&#xD;
&#xD;
               1. Male condom and intravaginal spermicide plus hormonal contraceptives (birth&#xD;
                  control pills, injectable/ implantable/ insertable hormonal birth control&#xD;
                  products, transdermal patch) in use for at least 3 months&#xD;
&#xD;
               2. Male condom and IUD in place for at least 3 months plus spermicide;&#xD;
&#xD;
               3. Male condom and diaphragm plus spermicide&#xD;
&#xD;
               4. Male condom and cervical cap plus spermicide&#xD;
&#xD;
               5. Vasectomy for 6 months minimum prior to the first dose of study drug&#xD;
&#xD;
             Male subjects also agree to not donate sperm from the time of taking the first dose of&#xD;
             study drug until 3 months after the last dose of study drug&#xD;
&#xD;
          5. Subject with a body mass index (BMI) of 18.0 to 32.0 kg/m2 at screening&#xD;
&#xD;
          6. Subject is a current non-smoker and has not used any nicotine containing product&#xD;
             within 3 months prior to screening&#xD;
&#xD;
          7. Subjects who are considered generally healthy upon completion of medical history,&#xD;
             physical examination, vital signs, screening laboratory results and screening ECG as&#xD;
             judged by the investigator&#xD;
&#xD;
          8. Subjects who are willing and able to comply with the visit schedule, treatment plan,&#xD;
             laboratory tests, pharmacokinetic sampling schedule and other study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Females who are pregnant or are breast feeding&#xD;
&#xD;
          2. History of significant hypersensitivity reaction to any substance or drug&#xD;
&#xD;
          3. Clinically relevant history or evidence of significant gastrointestinal, hepatic,&#xD;
             renal, endocrine, pulmonary, neurological, psychiatric, cardiovascular, hematologic,&#xD;
             dermatologic, immunologic disease or any other condition known to interfere with the&#xD;
             absorption, distribution, metabolism or distribution of drugs that in the opinion of&#xD;
             the investigator would jeopardize the safety of the subject or impact validity of&#xD;
             study results&#xD;
&#xD;
          4. Clinically significant vital signs in the opinion of the investigator at screening or&#xD;
             prior to study drug administration&#xD;
&#xD;
          5. History of clinically significant cardiovascular illness including but not confined&#xD;
             to: angina pectoris or myocardial infarction, coronary or peripheral artery bypass&#xD;
             graft, congestive heart failure, or clinically significant cardiac arrhythmia in the&#xD;
             opinion of the investigator&#xD;
&#xD;
          6. History of clinically significant thrombotic or hemorrhagic events (including but not&#xD;
             confined to stroke and transient ischemic attacks); history of bleeding diathesis or&#xD;
             coagulopathy; history or presence of gastrointestinal or other conditions with risk of&#xD;
             perforation; presence of a non-healing wound, ulcer or fracture in the opinion of the&#xD;
             investigator&#xD;
&#xD;
          7. Presence of out-of-range cardiac interval (PR &lt; 110 msec, PR &gt; 200 msec, QRS &lt; 60&#xD;
             msec, QRS &gt;110 msec and QTcF &gt; 450 msec) at screening or the pre-dose ECG or other&#xD;
             clinically significant ECG abnormalities in the opinion of the investigator&#xD;
&#xD;
          8. History of regular alcohol consumption exceed 7 drinks for females and 14 drinks per&#xD;
             week for males within 6 months of screening or a positive alcohol breath test at&#xD;
             screening and prior to study drug administration&#xD;
&#xD;
          9. History of significant drug abuse within one year prior to screening&#xD;
&#xD;
         10. Any clinically significant illness or surgery in the previous 30 days before day 1 of&#xD;
             this study&#xD;
&#xD;
         11. Use of any enzyme-modifying drugs, including strong inhibitors of cytochrome P450&#xD;
             (CYP) enzymes (such as cimetidine, fluoxetine, quinidine, erythromycin, ciprofloxacin,&#xD;
             fluconazole, ketoconazole, diltiazem and HIV antivirals) and strong inducers of CYP&#xD;
             enzymes (such as barbiturates, carbamazepine, glucocorticoids, phenytoin, rifampin and&#xD;
             St John's Wort), in the previous 30 days before day 1 of this study&#xD;
&#xD;
         12. Use of any drugs known to induce or inhibit hepatic metabolism (inducers such as&#xD;
             rifampin, barbiturates, carbamazepine, phenytoin, glucocorticoid, omeprazole;&#xD;
             inhibitors such as antidepressants (SSRI), cimetidine, diltiazem, macrolides,&#xD;
             imidazoles, neuroleptics, verapamil, fluroquinolones, antihistamines) in the previous&#xD;
             30 days before day 1 of the study&#xD;
&#xD;
         13. Use of any other prescription medications in the previous 14 days before day 1 of this&#xD;
             study&#xD;
&#xD;
         14. Use of any over-the-counter (OTC) products including cold preparations, multivitamins&#xD;
             and dietary supplements used for therapeutic benefits and antacid preparations in the&#xD;
             previous 7 days before day 1 of this study&#xD;
&#xD;
         15. Use of Acetylsalicylic Acid (ASA) or NSAIDs (or any product containing ASA or NSAIDs)&#xD;
             in the previous 7 days before day 1 of this study&#xD;
&#xD;
         16. Use of MAO inhibitors within 30 days of day 1 of the study&#xD;
&#xD;
         17. Positive urine drug screen or urine cotinine test at screening and prior to study drug&#xD;
             administration&#xD;
&#xD;
         18. Positive results to HIV, HBsAg or anti-HCV tests at screening&#xD;
&#xD;
         19. Subjects who took an Investigational Product (in another clinical trial) in the&#xD;
             previous 30 days (90 days for biologics) before day 1 of this study&#xD;
&#xD;
         20. Donation of plasma within 7 days prior to dosing. Any donation/loss of blood or blood&#xD;
             products within 3 months of the screening visit&#xD;
&#xD;
         21. Prior exposure to MGCD265&#xD;
&#xD;
        No subjects will be allowed to enroll in this study more than once (i.e. if the study is&#xD;
        conducted with more than 1 group).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vince &amp; Associates Clinical Research, Inc.</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>August 23, 2013</study_first_submitted>
  <study_first_submitted_qc>August 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 28, 2013</study_first_posted>
  <last_update_submitted>January 6, 2015</last_update_submitted>
  <last_update_submitted_qc>January 6, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>c-Met</keyword>
  <keyword>VEGFR</keyword>
  <keyword>Ron</keyword>
  <keyword>Cancer</keyword>
  <keyword>Tumor</keyword>
  <keyword>Safety</keyword>
  <keyword>Phase 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

